UnknownPhase 2NCT02555800

Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

Studying Recurrent respiratory papillomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centro de Investigación en. Enfermedades Infecciosas, Mexico
Principal Investigator
Gustavo Reyes-Terán, M.D., D.O
Centro de Investigación en. Enfermedades Infecciosas, Mexico
Intervention
Bevacizumab(drug)
Enrollment
36 target
Eligibility
All sexes
Timeline
20142017

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02555800 on ClinicalTrials.gov

Other trials for Recurrent respiratory papillomatosis

Additional recruiting or active studies for the same condition.

See all trials for Recurrent respiratory papillomatosis

← Back to all trials